Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s share price fell 6.6% during mid-day trading on Tuesday . The company traded as low as $2.14 and last traded at $2.14, with a volume of 61,425 shares. The stock had previously closed at $2.29.

A number of research firms have recently issued reports on CNAT. FBR & Co restated a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Monday, April 18th. Brean Capital restated a “buy” rating and issued a $7.00 price target (down from $13.00) on shares of Conatus Pharmaceuticals in a research note on Monday, May 9th. Finally, Roth Capital began coverage on Conatus Pharmaceuticals in a research note on Friday, July 1st. They issued a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $9.66.

The company’s 50 day moving average price is $2.14 and its 200-day moving average price is $2.20. The firm’s market cap is $45.10 million.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.35). During the same period last year, the company earned ($0.38) EPS. Equities analysts predict that Conatus Pharmaceuticals Inc. will post ($1.53) EPS for the current year.

An institutional investor recently raised its position in Conatus Pharmaceuticals stock. Jennison Associates raised its position in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 0.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 659,067 shares of the biotechnology company’s stock after buying an additional 3,983 shares during the period. Jennison Associates owned approximately 3.32% of Conatus Pharmaceuticals worth $2,933,000 as of its most recent SEC filing.

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.